Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 626 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ALIMTA Clear all
Completed Phase 2 Interventional Results available

Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)

NCT00942825
View directory record Official record
Conditions
Metastatic Non-squamous Non Small Cell Lung Cancer
Interventions
CBP501 + Cisplatin + Pemetrexed, Cisplatin + Pemetrexed
Drug
Lead sponsor
CanBas Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Las Vegas, Nevada • Hershey, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 25, 2026, 12:08 PM EDT
Terminated Not applicable Interventional Results available

Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer

NCT02145078
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
docetaxel, pemetrexed disodium, gemcitabine hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 25, 2026, 12:08 PM EDT
Terminated Phase 2 Interventional Results available

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

NCT02119650
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Carcinoma)
Interventions
Ruxolitinib, Placebo, Pemetrexed, Cisplatin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 25, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Results available

Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer

NCT00906282
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
12
States / cities
Fort Myers, Florida • Augusta, Georgia • Gainesville, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 25, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer

NCT00293579
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pemetrexed
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 25, 2026, 12:08 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

NCT02041533
View directory record Official record
Conditions
Stage IV or Recurrent Non-Small Cell Lung Cancer
Interventions
Nivolumab, Gemcitabine, Cisplatin, Carboplatin, Paclitaxel, Pemetrexed
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
36
States / cities
Mobile, Alabama • Gilbert, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 25, 2026, 12:08 PM EDT
Terminated Phase 1 Interventional Results available

Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

NCT00310050
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
pemetrexed disodium, Radiotherapy
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 25, 2026, 12:08 PM EDT
Terminated Phase 2 Interventional Results available

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)

NCT02357147
View directory record Official record
Conditions
Mesothelioma, Malignant
Interventions
Placebo, Amatuximab, Pemetrexed, Cisplatin
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
La Jolla, California • Newark, Delaware • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 25, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

NCT00198133
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma
Interventions
Premetrexed (Alimta)
Drug
Lead sponsor
Patrick Joseph Loehrer Sr.
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 25, 2026, 12:08 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT03178552
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
12
States / cities
Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 12:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

NCT01126736
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
eribulin mesylate, pemetrexed, Eribulin mesylate (eribulin; E7389)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Fort Myers, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 25, 2026, 12:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

NCT03768063
View directory record Official record
Conditions
Cancer
Interventions
Atezolizumab, Bevacizumab, Alectinib, Cobimetinib, Vemurafenib, FAP IL2V, Venetoclax, Enzalutamide, Pembrolizumab, Sunitinib, Niraparib, Cabozantinib, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
7
States / cities
Aurora, Colorado • Trumbull, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 12:08 PM EDT
Active, not recruiting Phase 2 Interventional

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

NCT03786692
View directory record Official record
Conditions
Non-Small Cell Carcinoma of Lung, TNM Stage 4
Interventions
Arm A, Arm B
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 12:08 PM EDT
Terminated Phase 2 Interventional Results available

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

NCT01646125
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer (NSCLC)
Interventions
AUY922, Docetaxel, Pemetrexed
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Rockville, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 25, 2026, 12:08 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

NCT00974584
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
GDC-0941, bevacizumab, carboplatin, cisplatin, paclitaxel, pemetrexed
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 25, 2026, 12:08 PM EDT
Terminated Phase 2 Interventional

Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer

NCT00216216
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Pemetrexed
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
16
States / cities
Newark, Delaware • Galesburg, Illinois • Elkhart, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 25, 2026, 12:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

NCT00216203
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pemetrexed, Cetuximab
Drug
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
11
States / cities
Galesburg, Illinois • Bloomington, Indiana • Elkhart, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 25, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer

NCT01829113
View directory record Official record
Conditions
Non Squamous Non Small Cell Lung Cancer
Interventions
OGX-427, Placebo
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
16
States / cities
Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 25, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Results available

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

NCT01087970
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Pemetrexed, Cetuximab, Carboplatin, Cisplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
21
States / cities
Jonesboro, Arkansas • Waterbury, Connecticut • Fort Myers, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 25, 2026, 12:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Divarasib, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
16
States / cities
Duarte, California • Huntington Beach, California • Irvine, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00117962
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, carboplatin, pemetrexed disodium, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
71
States / cities
Arroyo Grande, California • Castro Valley, California • Hayward, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 25, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy

NCT00063570
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Pemetrexed, Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
6
States / cities
Aurora, Colorado • Plantation, Florida • Morrisville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2009 · Synced Oct 25, 2026, 12:08 PM EDT
Terminated Phase 2 Interventional

Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy

NCT00096187
View directory record Official record
Conditions
Gestational Trophoblastic Tumor
Interventions
pemetrexed disodium
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Up to 120 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
25
States / cities
Birmingham, Alabama • Burbank, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 25, 2026, 12:08 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

NCT01860040
View directory record Official record
Conditions
Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer, Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer
Interventions
Cisplatin, Pemetrexed, Gemcitabine
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 25, 2026, 12:08 PM EDT